PR.com: Business Directory, Press Releases, Jobs, Products, Services, Articles
 
Businesses Articles Press Releases Follow @PRcom
Press Release Pricing | News by Category | News by Country | News by US Region | Recent News | PR.com News on Your Site
 

Press Releases

 
iHealthcareAnalyst, Inc.

Press Release


Receive press releases from iHealthcareAnalyst, Inc.: By Email RSS Feeds:

Glaucoma Therapeutics Market Analysis and Forecast 2017-2021, Upcoming Report by iHealthcareAnalyst, Inc.


Glaucoma Therapeutics Market by Drug Class (Alpha Agonist, Beta Blockers, Carbonic Anhydrase Inhibitor, Cholinergic, Combined Medication, Prostaglandin Analogs), End Users (Ambulatory Surgical Centers, Hospitals, Ophthalmic Clinics) and Forecast 2017-2021

Maryland Heights, MO, April 13, 2017 --(PR.com)-- Glaucoma is a progressive optic neuropathy that is a leading cause of irreversible blindness worldwide. Chronic progressive optic neuropathy, it can lead to severe disability and blindness. Glaucoma is classified according to whether it is congenital or acquired. Glaucoma is usually associated with an increase in intraocular pressure (IOP). The mainstream glaucoma therapies include topical medications, laser treatments and surgical procedures. Ocular hypertension is a major risk factor for the development of glaucoma and current glaucoma therapy is directed at lowering intraocular pressure. The most widely prescribed glaucoma drugs include the prostaglandin analogs (PGAs) that lower IOP by increasing the aqueous drainage through the unconventional uveoscleral outflow pathway, whereas the non-PGA drug classes such as the beta blockers, alpha agonists, and carbonic anhydrase inhibitors, lower IOP by decreasing the production of aqueous humor. Several new drug classes such as Adenosine A1 receptor agonists, selective Rho kinase inhibitors, melatonin agonists, and rho kinase/norepinephrine transporter (ROCK/NET) inhibitors have entered clinical development.

Browse Glaucoma Therapeutics Market by Drug Class (Alpha Agonist, Beta Blockers, Carbonic Anhydrase Inhibitor, Cholinergic, Combined Medication, Prostaglandin Analogs), End Users (Ambulatory Surgical Centers, Hospitals, Ophthalmic Clinics) and Forecast 2017-2021 at https://www.ihealthcareanalyst.com/report/glaucoma-therapeutics-market/

The global glaucoma therapeutics market segmentation is based on drug class (alpha agonist, beta blockers, carbonic anhydrase inhibitor, cholinergic, combined medication, prostaglandin analogs), end users (ambulatory surgical centers, hospitals, ophthalmic clinics).

The global glaucoma therapeutics market report provides market size (Revenue USD Million 2014 to 2021), market share, trends and forecasts growth trends (CAGR%, 2017 to 2021). The global glaucoma therapeutics market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global glaucoma therapeutics market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and also tracks the major competitors operating in the market by company overview, financial snapshot, key products, technologies and services offered, market share analysis and recent trends in the global market.

Major players operating in the global glaucoma therapeutics market and profiled in this report include Aerie Pharmaceuticals Inc., Allergan Inc., Merck & Co., Novartis AG, Pfizer Inc., Santen Pharmaceuticals, and Valeant Pharmaceuticals, Inc.

1. Drug Class
1.1. Alpha Agonist
1.2. Beta Blockers
1.3. Carbonic Anhydrase Inhibitor
1.4. Cholinergic
1.5. Combined Medication
1.6. Prostaglandin Analogs
2. End Users
2.1. Ambulatory Surgical Centers
2.2. Hospitals
2.3. Ophthalmic Clinics
3. Geography (Region, Country)
3.1. North America (U.S., Canada)
3.2. Latin America (Brazil, Mexico, Rest of LA)
3.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
3.4. Asia Pacific (Japan, China, India, Rest of APAC)
3.5. Rest of the World
4. Company Profiles
4.1. Aerie Pharmaceuticals Inc.
4.2. Allergan Inc.
4.3. Merck & Co.
4.4. Novartis AG
4.5. Pfizer Inc.
4.6. Santen Pharmaceuticals
4.7. Valeant Pharmaceuticals, Inc.

To request Table of Contents and Sample Pages of this report visit:
https://www.ihealthcareanalyst.com/report/glaucoma-therapeutics-market/

About Us
iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.

In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.

Contact Us
iHealthcareAnalyst, Inc.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043
United States
Email: sales@ihealthcareanalyst.com

Website: https://www.ihealthcareanalyst.com
Contact Information
iHealthcareAnalyst, Inc.
Ana Aitawa
(314) 500-7508
Contact
https://www.ihealthcareanalyst.com/

Click here to view the list of recent Press Releases from iHealthcareAnalyst, Inc.
Promote Your Business